Navigation Links
New Generation Biofuels CEO to Present at the Rodman & Renshaw Annual Global Investment Conference
Date:11/7/2008

LAKE MARY, Fla., Nov. 7 /PRNewswire-FirstCall/ -- New Generation Biofuels Holdings, Inc. (Nasdaq: NGBF), a renewable fuels provider, today announced that David Gillespie, President & CEO, is scheduled to present at the Rodman & Renshaw Annual Global Investment Conference on Monday, November 10th, at 4:55pm Eastern Time. Management will also be available for one-on-one meetings during the day. The conference will be held at the New York Palace Hotel in New York City. The presentation will be webcast and can be viewed at http://www.wsw.com/webcast/rrshq14/ngbf/. Information about attending the conference can be found at http://www.rodmanandrenshaw.com/conferences.

About New Generation Biofuels Holdings, Inc.

New Generation Biofuels is a renewable fuels provider. We hold an exclusive license for North America, Central America and the Caribbean to commercialize proprietary technology to manufacture alternative biofuels from vegetable oils and animal fats that we intend to market as a new class of biofuel for power generation, heavy equipment, marine use and as heating fuel. We believe our proprietary biofuel can provide a cheaper, renewable alternative energy source with significantly lower emissions than traditional fuels. Our business model calls for establishing direct sales from manufacturing plants that we may purchase or build and sublicensing our technology to qualified licensees.

Forward Looking Statements

This news release contains forward-looking statements. These forward-looking statements concern our operations, prospects, plans, economic performance and financial condition and are based largely on our current beliefs and expectations. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by such forward-looking statements. The risks and uncertainties related to our business include all the risks attendant a development stage business in the volatile energy industry, including, without limitation, the risks set forth under the caption "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2008.

CONTACT:

David Gillespie, President & CEO

New Generation Biofuels, Inc.

713-973-5720

Rob Schatz

Wolfe Axelrod Weinberger Associates, LLC

212-370-4500


'/>"/>
SOURCE New Generation Biofuels Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Osteotechs Next Generation Grafting Material, MagniFuse(TM) Bone Graft, a Breakthrough in Bone Regeneration; MagniFuse(TM) Bone Graft seeks to redefine the standard of care in the U.S. bone graft substitute market estimated to be in excess of $1.2 billio
2. Osteotech Receives FDA Clearance for its Next Generation Grafting Material
3. Pioneer(R) Surgical Technology Announces Market Release of FortrOss(TM), a Next Generation Bone Void Filler
4. Spring Point Project Welcomes Second Generation Medical-Grade Piglets
5. CorMatrix Cardiovascular to Present Data on Its Next Generation ECM Technology(TM) at Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference in Washington, D.C.
6. Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent
7. Targeting Metastatic Cancer From the Inside: Epeius Biotech Reveals a New Generation of Tools for Medical Gene Delivery
8. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
9. Oklahoma CyberKnife Center Cuts Treatment Time in Half With Next Generation CyberKnife Technology
10. Introducing the next generation of chemical reactors
11. First Coast Oncology to Offer Next Generation Proton Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
Breaking Biology Technology:
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):